The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repur-posing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, anti-histaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A in-hibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.

In silico drug repurposing in COVID-19. A network-based analysis / Sibilio, Pasquale; Bini, Simone; Fiscon, Giulia; Sponziello, Marialuisa; Conte, Federica; Pecce, Valeria; Durante, Cosimo; Paci, Paola; Falcone, Rosa; Norata, Giuseppe Danilo; Farina, Lorenzo; Verrienti, Antonella. - In: BIOMÉDECINE & PHARMACOTHÉRAPIE. - ISSN 0753-3322. - 142(2021), pp. 1-10. [10.1016/j.biopha.2021.111954]

In silico drug repurposing in COVID-19. A network-based analysis

Sibilio, Pasquale;Bini, Simone;Fiscon, Giulia;Sponziello, Marialuisa;Conte, Federica;Pecce, Valeria;Durante, Cosimo;Paci, Paola;Falcone, Rosa;Farina, Lorenzo;Verrienti, Antonella
2021

Abstract

The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repur-posing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, anti-histaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A in-hibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
File allegati a questo prodotto
File Dimensione Formato  
Sibilio_Silico-drug_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.61 MB
Formato Adobe PDF
2.61 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1564553
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact